Health Economics›Cholangiocarcinoma›Metastatic disease, all lines of therapy

Metastatic disease, all lines of therapy

Cholangiocarcinoma · 16 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~16.5 mo	~13.9 mo	~36	~R 10 330 390 PFS proxy · indirect	7
Erlotinib and Bevacizumab Variant #01	—	R 52 071	28d	~16.4 mo	~49.1 mo	~18	~R 937 282 PFS proxy · indirect	7
GEMOX-B Variant #01	—	R 42 835	28d	—	—	—	—	—
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	—	~11.1 mo	—	—	8
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	~4.7 mo	~6.8 mo	~3	~R 42 639 PFS proxy · indirect	31
Gemcitabine and Mitomycin Variant #01	—	R 7 409	28d	—	—	—	—	—
FULV and Gemcitabine Variant #02	—	R 3 219	21d	—	—	—	—	—
Gemcitabine and S-1 Variant #01 Partial	—	R 2 843	21d	—	~26.1 mo	—	—	2
Capecitabine and Mitomycin Variant #01	—	R 2 711	28d	—	—	—	—	—
GemOx Variant #01	—	R 2 335	14d	~5.0 mo	~9.0 mo	~11	~R 25 688 PFS proxy · indirect	5
Capecitabine monotherapy Variant #17	—	R 2 219	21d	~5.7 mo	~7.5 mo	~9	~R 19 974 PFS proxy · indirect	11
FELV Variant #01	—	R 1 934	21d	—	~12.0 mo	—	—	—
Gemcitabine, Cisplatin, S-1 Variant #01 Partial	—	R 1 546	14d	—	~13.5 mo	—	—	1
FULV Variant #01	—	R 1 466	35d	~5.6 mo	~13.1 mo	~5	~R 7 330 PFS proxy · indirect	15
Nivolumab monotherapy Variant #01 Partial	—	—	14d	~1.8 mo	~10.9 mo	~4	—	6
Pemigatinib monotherapy Variant #01 Partial	—	—	21d	—	—	—	—	—

16 of 16 regimens shown